Abstract
Data are limited for real-world LC-FAOD outcomes. Major clinical manifestations of LC-FAOD were assessed as primary outcomes in triheptanoin clinical trials and include rhabdomyolysis, hypoglycemia, and cardiomyopathy. This analysis aims to quantify the real-world burden of LC-FAOD in terms of major clinical manifestations by treatment periods.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
